

Form PTO-1449 (Modified)	Atty. Docket No. 30754/39959	Serial No. 10/823,906
INFORMATION DISCLOSURE STATEMENT		
Applicant(s) David E. Clarke		
Filing Date April 14, 2004		Art Unit 1614

O I P E 142
MAY 17 2006
U. S. TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)
A1 /CH/	3,598,122	8/10/1971	Zaffaroni	204	607	
A2 /CH/	4,788,189	11/29/1988	Glazer	514	221	
A3 /CH/	4,965,074	10/23/1990	Leeson	424	449	
A4 /CH/	4,971,079	11/20/1990	Talapin	131	159	
A5 /CH/	5,016,652	5/21/1991	Rose et al.	131	270	
A6 /CH/	5,227,391	7/13/1993	Caldwell	514	343	
A7 /CH/	5,272,155	12/21/1993	Arneric et al.	514	315	
A8 /CH/	5,342,623	8/30/1994	Enscoe et al.	424	448	
A9 /CH/	5,635,203	6/30/1997	Gale et al.	424	448	
A10 /CH/	5,780,051	7/14/1998	Eswara et al.	424	449	
A11 /CH/	5,977,131	11/02/1999	Nagel	514	300	
A12 /CH/	6,004,970	12/21/1999	O'Malley et al.	514	282	
A13 /CH/	6,280,761	8/28/2001	Santus	424	435	
A14 /CH/	6,280,763	8/28/2001	Midha et al.	424	448	
A15 /CH/	6,344,222	2/05/2002	Cherukuri et al.	426	6	
A16 /CH/	6,495,605	12/17/2002	McCullough et al.	514	646	
A17 /CH/	6,582,737	6/24/2003	Hirsh et al.	424	751	
A18 /CH/	6,596,740	7/22/2003	Jones	514	343	
A19 /CH/	6,620,428	9/16/2003	Hoeck et al.	424	449	
A20 /CH/	6,630,467	10/07/2003	O'Neill	514	233.2	
A21 /CH/	6,677,379	1/13/2004	Sikorski	514	649	
A22 /CH/	6,699,497	3/02/2004	van Osdol et al.	424	448	

EXAMINER: /Carlic Huynh/	DATE CONSIDERED: 08/21/2007
--------------------------	-----------------------------

Form PTO-1449 (Modified)	Atty. Docket No. 30754/39959	Serial No. 10/823,906
INFORMATION DISCLOSURE STATEMENT		
Applicant(s) David E. Clarke		
Filing Date April 14, 2004	Art Unit 1614	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation Yes	Translation No

OTHER DOCUMENTS

C1 /CH/	ALLGAYER, Hubert, <i>Gastrointestinal Pharmacology</i> , Sulfasalazine and 5-ASA Compounds, 21:643-658, 1992.
C2 /CH/	FREE et al., <i>Brain Research</i> , Surface and Intracellular Nicotinic Receptors Expressed in Intact Adrenal Chromaffin Cells: Direct Measurements Using [3H]epibatidine; 974:60-9, 2003.
C3 /CH/	GUSLANDI, M., <i>International Journal of Colorectal Disease</i> , Long-Term Effects of a Single Course of nicotine Treatment in Acute Ulcerative Colitis: Remission Maintenance in a 12-Month Follow-Up Study, 14:361-262, 1999.
C4 /CH/	IOANNIDES et al., <i>New England Journal of Medicine</i> , Rectal Administration of Metronidazole Provides Therapeutic Plasma Levels in Postoperative Patients, 305:1569-70, 1981.
C5 /CH/	Japanese Pharmacology & Therapeutics, 22:93-121 (1994).
C6 /CH/	KAWASHIMA et al., <i>Life Sciences</i> , The Lymphocytic Cholinergic System and its Biological Functions, 72:2101-9, 2003.
C7 /CH/	LASHNER et al., <i>Digestive Diseases and Sciences</i> , Testing Nicotine Gum for Ulcerative Colitis Patients, 35:827-32, 1990.
C7 /CH/	LI et al., <i>Current Gastroenterology. Reports</i> , Assessing Disease Activity and Disease Activity Indices for Inflammatory Bowel Disease, 4:490-96, 2002.
C9 /CH/	LICHTIGER et al., <i>New England Journal of Medicine</i> , Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, 330:1841-1845, 1994.
C10 /CH/	MELGAR et al., <i>Clinical and Experimental Immunology</i> , Over-Expression of Interleukin 10 in Mucosal T Cells of Patients with Active Ulcerative Colitis, 134:127-37, 2003
C11 /CH/	RACHMILEWITZ, D., <i>British Medical Journal</i> , Coated Mesalazine (5-aminosalicylic acid) Versus Sulphasalazine in the Treatment of Active Ulcerative Colitis: A Randomised Trial, 298:82-82, 1989.
C12 /CH/	ROBINSON et al., <i>Journal of Laboratory and Clinical Medicine</i> , Regulation of Neutrophils in Ulcerative Colitis by Colonic Factors: A Possible Mechanism of Neutrophil Activation and Tissue Damage, 130:590-602, 1997.
C13 /CH/	SANDBORN, W., <i>American Journal of Gastroenterology</i> , Nicotine Therapy for Ulcerative Colitis: A Review of Rationale, Mechanisms, Pharmacology and Clinical Results, 94:1161-1171, 1999.

EXAMINER: /Carlic Huynh/	DATE CONSIDERED: 08/21/2007
--------------------------	-----------------------------

Form PTO-1449 (Modified)

Atty. Docket No.
30754/39959Serial No.
10/823,906**INFORMATION DISCLOSURE STATEMENT**Applicant(s)
David E. ClarkeFiling Date
April 14, 2004Art Unit
1614

C14 /CH/	SINGH, PARMINDER et al., "Iontophoresis in Drug Delivery: Basic Principles and Applications", <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 11:161-213, 1994.
C15 /CH/	Sogo Rinsho (Comprehensive Clinic), 43:1725-1729 (1994).
C16 /CH/	TAMBOLI et al., <i>Best Practice and Research Clinical Gastroenterology</i> , Probiotics in Inflammatory Bowel Disease: A Critical Review, 17:805-20, 2003.
C17 /CH/	TANG et al., <i>Cellular Signalling</i> , CaM Kinase II-Dependent Phosphorylation of Myogenin Contributes to Activity-Dependent Suppression of nAChR Gene Expression in Developing Rat Myotubes, 16:551-63, 2004.
C18 /CH/	THOMAS et al., <i>New England Journal of Medicine</i> , Transdermal Nicotine as Maintenance Therapy for Ulcerative Colitis, 332:988-92, 1995.
C19 /CH/	The Merck Manual, Seventeenth Edition, p. 309, 1999.
C20 /CH/	WICK, Steven, "Developing a Drug-In-Adhesive Design for Transdermal Drug Delivery", <i>Adhesives Age</i> , 38(10):18-24, 1995.

EXAMINER:	/Carlic Huynh/	DATE CONSIDERED:	08/21/2007
-----------	----------------	------------------	------------